Cosentyx
(Secukinumab)
Primary Uses
Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and related spondyloarthropathies per label and payer criteria.
Mechanism of Action
Monoclonal antibody that neutralizes IL‑17A, reducing inflammatory signaling.
Pre-treatment / baseline requirement
Screen for active infection; TB screening (IGRA/PPD) and hepatitis B screening are commonly required for many biologics; baseline CBC and CMP/LFTs are often requested; review vaccination status (avoid live vaccines during therapy per PI); confirm pregnancy status when clinically appropriate; review prior biologic exposure and infection history. Assess history of inflammatory bowel disease (IBD), as flares may occur in susceptible individuals.
Common side effects
Upper respiratory symptoms, diarrhea, injection-site reactions.
Serious adverse effects / key risks
Serious infection risk; hypersensitivity; potential IBD exacerbation.
Clinical notes
Live vaccines are generally avoided during therapy; confirm immunization status in advance.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and related spondyloarthropathies
How it works
Targets IL‑17 to reduce inflammation.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Upper respiratory symptoms, diarrhea, injection-site reactions.
Get urgent help for
Serious infection risk; hypersensitivity; potential IBD exacerbation.
On treatment day
plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.